Overview

An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms

Status:
Completed

Trial end date:
2005-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if galantamine is an effective agent for the treatment of the cognitive abnormalities, negative symptoms, and /or behavioral impairments seen in schizophrenia.

Phase:

N/A

Details

Lead Sponsor:

University of Maryland
University of Maryland, Baltimore

Treatments:

Galantamine